Avtor/Urednik		Bratuš, Dejan
Naslov		Monoterapija s ciproteron acetatom pri zdravljenju napredovalega raka na prostate [!]
Prevedeni naslov		Cyproterone acetate monotherapy in the management of advanced prostate cancer
Tip		članek
Vir		In: Rak prostate : [zbornik predavanj] : [the book of lectures] Slovenj Gradec : Oddelek za urologijo, Splošna bolnišnica : = Department of Urology, General Hospital
Leto izdaje		2009
Obseg		str. 54-55
Jezik		slv
Abstrakt		Rak na prostati je najpogostejši malignom pri starejšem moškem. Kljub sodobnim preiskovalnim metodam in ozaveščanju moških o potrebi po rednih uroloških pregledih se rak na prostati še vedno pogosto odkrije šele, ko je že v napredovali fazi in ni več omejen na prostato. V teh primerih velja za standardno terapijo hormonska ablacija. Le to lahko naredimo ba več načinov, eden izmed njih je tudi možnost monoterapije z antiandrogeni. Ciproteron acetat je eden izmed najstarejših antiandrogenov in je nekaj čas bil celo edini antiandrogen, ki je bil na voljo za zdravljenje raka na prostati. Je steroidni antiandrogen z dvojnim delovanjem. Kot antiandrogen blokira delovanje androgenov na nivoju androgenih receptorjev. Zraven tega ima tudi antigonadotropni učinek in znižuje plazemski nivo LH in testosterona. Klinični podatki o tem zdravilu sicer segajo v 80. in 90. leta prejšnjega stoletja, vsekakor pa potrjujejo njegovo učinkovitost v primerjavi z ostalimi metodami androgene deprivacije. Kljub svoji starosti ga kliniki po svetu še vedno redno uporabljajo in ostaja koristno zdravilo za zdravljenje napredovalega raka na prostati.Prostate cancer is the most common cancer in older men. In spite of the modern diagnostic tools and the popularization of need for regular urological examinations among men it is still frequently diagnosed in an advanced phase when it is no longer limited to prostate. In this cases standard therapy comprises of hormonal ablation. This can be achieved by several methods, one of them being a possibility of antiandrogen monotherapy. Cyproterone acetate is one of the oldest antiandrogens and for some time it was the only antiandrogen available for treatment of prostate cancer. It is a steroidal antiandrogen with double action. As an antiandrogen it blocks the action of androgens at the level of androgen receptors. In addition, it has a mild antigonadotropic effect and lowers plasma LH and testosterone levels. Clinical trials date back to 1980's and 1990's but nevertheless confirm its effectiveness in comparison with other methods of androgen deprivation. In spite of its having come of age, it is still frequently used by clinicians and remains a useful drug in the management of advanced prostate cancer.
Deskriptorji		Prostatic Neoplasms Prostata, novotvorbe Cyproterone Acetate Ciproteron acetat therapy Zdravljenje
Proste vsebinske oznake		antiandrogena monoterapija